HE4, CA125, the Risk of Malignancy Algorithm and the Risk of Malignancy Index and complex pelvic masses - a prospective comparison in the pre-operative evaluation of pelvic masses in an Australian population
- PMID: 26172511
- DOI: 10.1111/ajo.12363
HE4, CA125, the Risk of Malignancy Algorithm and the Risk of Malignancy Index and complex pelvic masses - a prospective comparison in the pre-operative evaluation of pelvic masses in an Australian population
Abstract
Background: Human epididymis protein 4 (HE4) has been proposed as a novel biomarker for the diagnosis of epithelial ovarian cancer. Using HE4 and CA125, the risk of malignancy algorithm (ROMA) has been shown to be effective in the stratification of epithelial ovarian cancer risk.
Aims: To determine the effectiveness of HE4 and ROMA in the diagnosis of malignancy of women presenting with a complex pelvic mass in an Australian population and to compare it with CA125 and the risk of malignancy index (RMI).
Materials and methods: Prospective recruitment of women was conducted between October 2012 and March 2014 (n = 50). CA125 and HE4 serum concentrations were collected and stored for subsequent analysis. Sensitivities, specificities, positive predictive values (PPV) and negative predictive values (NPV) were calculated for HE4, CA125, ROMA and the RMI. Receiver operating characteristic (ROC) area under the curves (AUC) were also calculated for comparison.
Results: There was a higher HE4 level in women with ovarian cancer compared with women with benign pathology (P = 0.008), and this observation was seen in benign versus stage 1 ovarian cancer women (P = 0.025). HE4 had a better specificity than CA125 for the diagnosis of ovarian cancer in all women (P = 0.022), and this effect was also observed in premenopausal women (P = 0.012). Furthermore, the ROC-AUC for HE4 was superior than CA125 in all women (P = 0.0451). The ROMA algorithm was not inferior to the RMI calculation in this population.
Conclusions: In an Australian population, HE4 and ROMA are useful in the diagnosis of epithelial ovarian cancer.
Keywords: CA125; HE4; ovarian cancer; risk of ovarian malignancy algorithm; risk of ovarian malignancy index.
© 2015 The Royal Australian and New Zealand College of Obstetricians and Gynaecologists.
Similar articles
-
Evaluation of HE4, CA125, risk of ovarian malignancy algorithm (ROMA) and risk of malignancy index (RMI) as diagnostic tools of epithelial ovarian cancer in patients with a pelvic mass.Gynecol Oncol. 2012 Nov;127(2):379-83. doi: 10.1016/j.ygyno.2012.07.106. Epub 2012 Jul 24. Gynecol Oncol. 2012. PMID: 22835718 Clinical Trial.
-
Comparison of HE4, CA125, and Risk of Ovarian Malignancy Algorithm in the Prediction of Ovarian Cancer in Korean Women.J Korean Med Sci. 2015 Dec;30(12):1777-83. doi: 10.3346/jkms.2015.30.12.1777. Epub 2015 Nov 30. J Korean Med Sci. 2015. PMID: 26713052 Free PMC article.
-
A multicenter clinical trial validating the performance of HE4, CA125, risk of ovarian malignancy algorithm and risk of malignancy index.Gynecol Oncol. 2018 Oct;151(1):159-165. doi: 10.1016/j.ygyno.2018.08.025. Epub 2018 Aug 24. Gynecol Oncol. 2018. PMID: 30149898 Clinical Trial.
-
HE4 in the differential diagnosis of ovarian masses.Clin Chim Acta. 2015 Jun 15;446:147-55. doi: 10.1016/j.cca.2015.03.047. Epub 2015 Apr 16. Clin Chim Acta. 2015. PMID: 25892674 Review.
-
[Ovarian tumor markers of presumed benign ovarian tumors].J Gynecol Obstet Biol Reprod (Paris). 2013 Dec;42(8):752-9. doi: 10.1016/j.jgyn.2013.09.030. Epub 2013 Nov 7. J Gynecol Obstet Biol Reprod (Paris). 2013. PMID: 24210243 Review. French.
Cited by
-
Evaluation of HE4, CA-125, Risk of Ovarian Malignancy Algorithm (ROMA) and Risk of Malignancy Index (RMI) in the Preoperative Assessment of Patients with Adnexal Mass.Oman Med J. 2016 Sep;31(5):336-44. doi: 10.5001/omj.2016.68. Oman Med J. 2016. PMID: 27602187 Free PMC article.
-
Diagnostic Models Combining Clinical Information, Ultrasound and Biochemical Markers for Ovarian Cancer: Cochrane Systematic Review and Meta-Analysis.Cancers (Basel). 2022 Jul 26;14(15):3621. doi: 10.3390/cancers14153621. Cancers (Basel). 2022. PMID: 35892881 Free PMC article. Review.
-
Current and Emerging Strategies for Tubo-Ovarian Cancer Diagnostics.Diagnostics (Basel). 2023 Oct 28;13(21):3331. doi: 10.3390/diagnostics13213331. Diagnostics (Basel). 2023. PMID: 37958227 Free PMC article. Review.
-
Menopausal status, ultrasound and biomarker tests in combination for the diagnosis of ovarian cancer in symptomatic women.Cochrane Database Syst Rev. 2022 Jul 26;7(7):CD011964. doi: 10.1002/14651858.CD011964.pub2. Cochrane Database Syst Rev. 2022. PMID: 35879201 Free PMC article. Review.
-
Determination of reference intervals of serum levels of human epididymis protein 4 (HE4) in Chinese women.J Ovarian Res. 2015 Nov 9;8:72. doi: 10.1186/s13048-015-0201-z. J Ovarian Res. 2015. PMID: 26552478 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous